Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Voyager Therapeutics (VYGR) EPS (Basic) (2016 - 2025)

Voyager Therapeutics (VYGR) has disclosed EPS (Basic) for 11 consecutive years, with -$0.47 as the latest value for Q4 2025.

  • Quarterly EPS (Basic) rose 21.67% to -$0.47 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$2.04 through Dec 2025, down 78.95% year-over-year, with the annual reading at -$2.04 for FY2025, 80.53% down from the prior year.
  • EPS (Basic) hit -$0.47 in Q4 2025 for Voyager Therapeutics, roughly flat from -$0.47 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $3.05 in Q1 2023 to a low of -$0.8 in Q2 2021.
  • Historically, EPS (Basic) has averaged -$0.16 across 5 years, with a median of -$0.5 in 2022.
  • Biggest five-year swings in EPS (Basic): tumbled 513.33% in 2022 and later skyrocketed 644.64% in 2023.
  • Year by year, EPS (Basic) stood at $0.15 in 2021, then crashed by 513.33% to -$0.62 in 2022, then soared by 298.39% to $1.23 in 2023, then crashed by 148.78% to -$0.6 in 2024, then increased by 21.67% to -$0.47 in 2025.
  • Business Quant data shows EPS (Basic) for VYGR at -$0.47 in Q4 2025, -$0.47 in Q3 2025, and -$0.57 in Q2 2025.